ClinicalTrials.gg
RecruitingNCT07706348Updated Jul 15, 2026

Intraperitoneal Irrigation of Ondansteron in Combination With Lidocaine in Acute Postoperative Pain

A Phase 1/2 interventional study of ondansteron in Acue Postoperative Pain, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Assiut University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 109 studies in Pain, Postoperative by Assiut University — 31 open to participants now, 32 under way, 5 of them phase 3. Pain, Postoperative · Assiut University.

Planned enrollment
106th of 108
20 · median 70
Started
2026
with 17 others
Phase 1/2
2 of 109
1 open now
Primary completion
2027-07
later than 15 of 31 live
Registered
95th of 109
by date

Among the 109 studies in Pain, Postoperative by Assiut University, this one is the 106th largest by planned enrollment of the 108 interventional ones that give a count, is one of 18 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 15 of the 31 other live ones, and was the 95th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

31 of the 109 studies in Pain, Postoperative by Assiut University are open now, in 1 country. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 31 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Pain, Postoperative by Assiut University, or all of them as a file.
02

Study summary

This study, therefore, aimed to investigate the effect of intraperitoneal administration of ondansetron in combination to lidocaine for postoperative pain management in patients undergoing lower abdominal cancer surgery.

Read the detailed description

Postoperative pain relief is very important issue in any surgery. The common postoperative pain management is traditionally based on opioids (1,2). Considering opioids' adverse effects such as nausea, vomiting, sedation, drowsiness, and urinary retention, recently there is a lot of interest for f inding a safe and effective pain treatment after operation. Local anesthetics intraperitoneal instillation is recognized as a useful technique for postoperative pain management. They can reduce inflammatory response after surgery and produce analgesia by blocking neural transmission at the site of tissue injury (5). 5-HT3-antagonists, including ondansetron, are commonly used as anti-emetics to prevent and treat chemotherapy-induced vomiting and nausea [7]. Several studies have shown that 5-HT3-antagonists pose anti-inflammatory and analgesic properties, suggesting a potential clinical role in pain management.

03

Conditions studied

  • Acue Postoperative Pain

Browse trials for

Keywords

  • postoperative pain, ondasteron, intraperitoneal
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients
  • scheduled for major lower abdominal cancer surgeries.

Exclusion criteria

Exclusion Criteria:

  • patients with known allergy to the study drugs,
  • significant cardiac, respiratory, renal or hepatic disease,
  • (BMI) ≥30 kg/m2;
  • allergy to study drugs
  • history of opioid use for pain management the time of enrolment or drug addiction,
  • who had used benzodiazepine chronically,
  • stroke or psychiatric disease that could affect the perception of pain.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Ondansetron group (O group)

    8 mg ondansetron (4 mL) IP with 2% lidocain in dose 4mg/kg in total volume 30 ml instillation at the end of the procedure

    Drug: ondansteron

  • Placebo comparator
    control group (C group)

    lidocaune in dose 4mg/kg in total volume 30 ml with normal saline IP with lidocaine at the end of the procedure

    Drug: ondansteron

Interventions

  • Drugondansteron

    intraperitonel irrigation

06

What researchers measure

Primary outcomes

  1. total morphine consumption

    total amount of morphine consumption in mg in the first 24 hours for analgesia

    Time frame: in the first 24 hours postoperative

Secondary outcomes

  1. time of the first request of analgesia

    time between patients' extubation and first request of supplemental analgesia

    Time frame: first 24 hours postoperative

07

Study locations

1 of 1 sites recruiting
  • Assiut University - South Egypt Cancer Instiute
    Asyut, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jul 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2026
First posted
Jul 15, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07706348
Lead sponsor
Assiut University
Responsible party
Shereen Mamdouh (professor of anesthesia, ICU and pain management, Assiut University) — Principal investigator
First posted
Jul 15, 2026
Start date
Jun 1, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

shereen mamdouh kamal, professor
Contact
drshereenmamdouh@gmail.com
+201006279209

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion